Dianthus Therapeutics, Inc. /DE/

DNTH · Nasdaq · SIC 2834: Pharmaceutical Preparations
146
SEC Filings

Business Summary

PART I . Overview We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) enabling less frequent and more convenient self-administered subcutaneous (S.C.) injections suitable for...

Next Earnings

Q2 FY2026 — expected 2026-09-09

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionDNTHdiscussed_in_filing Cybersecurity
topic_mentionDNTHdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-092025-12-310001690585-26-000006EDGAR93K words
2025-03-112024-12-310000950170-25-037131EDGAR—
2024-03-212023-12-310000950170-24-034681EDGAR—
2023-03-232022-12-310000950170-23-009331EDGAR—
2022-03-082021-12-310001193125-22-068759EDGAR—
2021-03-032020-12-310001193125-21-066707EDGAR—
2020-03-032019-12-310001193125-20-059835EDGAR—
2019-03-192018-12-310001193125-19-078948EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-266920EDGAR28K words
2025-08-072025-06-300000950170-25-105030EDGAR—
2025-05-122025-03-310000950170-25-069226EDGAR—
2024-11-072024-09-300000950170-24-123285EDGAR—
2024-08-082024-06-300000950170-24-093948EDGAR—
2024-05-092024-03-310000950170-24-057022EDGAR—
2023-11-092023-09-300000950170-23-062070EDGAR—
2023-08-032023-06-300000950170-23-037605EDGAR—
2023-05-152023-03-310000950170-23-022192EDGAR—
2022-11-032022-09-300000950170-22-021603EDGAR—
2022-08-042022-06-300001193125-22-211881EDGAR—
2022-05-162022-03-310001193125-22-151014EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-260001690585-26-000010EDGAR11K words
2026-03-120001193125-26-103053EDGAR—
2026-03-090001193125-26-097555EDGAR—
2026-01-120001193125-26-009898EDGAR—
2025-11-050001193125-25-266867EDGAR—
2025-11-030001193125-25-262188EDGAR—
2025-10-160001193125-25-240858EDGAR—
2025-09-110001193125-25-200715EDGAR—
2025-09-080001193125-25-197751EDGAR—
2025-08-070000950170-25-105002EDGAR—

146 total filings indexed. 116 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001690585
TickerDNTH
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 89cc04cd149a9b2a576f0db045f8b285e06f06850d062123848ff95e0beaa93d
parent: ef10acd4f5496c50baf9cbc65602446469ef1d8e2460dad847e04f3c8192cfa6
content hash: 8d0a8e2d80213bd175ab90e87a80d9fa38f78cd5c76e73ff9f60bcee54f1edb1
signed: 2026-04-13T04:44:41.517Z
sources: 20 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf